{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:49:27Z","timestamp":1793296167923,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cld.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:15:53Z","timestamp":1692263753000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Primary Sclerosing Cholangitis Including Transplantation"],"prefix":"10.1016","volume":"28","author":[{"given":"William H.","family":"Wheless","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cld.2023.07.008_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2023.07.008_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 annual data report: liver","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2023.07.008_bib4","series-title":"StatPearls","article-title":"Ursodeoxyxholic acid","author":"Achufusi","year":"2023"},{"key":"10.1016\/j.cld.2023.07.008_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.07.008_bib6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, andomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.07.008_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose urdodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.07.008_bib8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2023.07.008_bib9","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients sith primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.07.008_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis- a pilot study","volume":"37","author":"Tabiban","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.07.008_bib14","unstructured":"Available at: www.clinical trials.gov (NCT03710122). (Accessed March 2nd, 2023)."},{"key":"10.1016\/j.cld.2023.07.008_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib16","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.cld.2023.07.008_bib17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol","volume":"108","author":"Hemme","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.07.008_bib18","doi-asserted-by":"crossref","first-page":"e00984","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Hatami","year":"2002","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cld.2023.07.008_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"JHepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib20","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A\u00a0double-blind placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangtitis and inflammatory bowel disease","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.14309\/ajg.0000000000001956","article-title":"A\u00a0randomized, dose-finding, proof-of-concept study of berberine ursodeoxycholate in patients with primary sclerosing cholangitis","volume":"117","author":"Kowdley","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farsenoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.07.008_bib26","first-page":"S1542","article-title":"Safety and sustained efficacy of the farsenoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC","author":"Trauner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.07.008_bib28","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","volume":"5","author":"Eksteen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2023.07.008_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtizumab for primary sclerosing cholangitis :Phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatolgoy"},{"key":"10.1016\/j.cld.2023.07.008_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/00365521.2019.1611917","article-title":"Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study","volume":"54","author":"Eaton","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.gie.2014.11.019","article-title":"The role of ERCP in benign diseases of the biliary tract","volume":"81","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cld.2023.07.008_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib34","unstructured":"Guidance to liver transplant programs and the national liver review board for: Adult Meld Exception review. Available at: https:\/\/optn.transplant.hrsa.gov\/media\/2847\/liver_guidance_adult_meld_201706.pdf. (Accessed March 4, 2023)."},{"key":"10.1016\/j.cld.2023.07.008_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.gtc.2018.01.002","article-title":"Liver transplant for cholangiocarcinoma","volume":"47","author":"Zamora-Valdes","year":"2018","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.cld.2023.07.008_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s40472-020-00283-1","article-title":"The changing landscapes in DCD liver transplantation","volume":"7","author":"Croome","year":"2020","journal-title":"Curr Transplant Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.07.008_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2018.12.033","article-title":"Survival advantage for patients accepting the offer of a circulatory death liver transplant","volume":"70","author":"Taylor","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.07.008_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2017.10.034","article-title":"The UK DCD Risk Score: a new proposal to define futility in donation-after-circulatory- death liver transplantation","volume":"68","author":"Schlegel","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.008_bib39","doi-asserted-by":"crossref","first-page":"e14579","DOI":"10.1111\/ctr.14579","article-title":"Applicability of the UK DCD risk score in the modern era of liver transplantation: a U.S. update","volume":"36","author":"Wu","year":"2022","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.cld.2023.07.008_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamasurg.2021.6781","article-title":"Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial","volume":"157","author":"Markmann","year":"2022","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.cld.2023.07.008_bib41","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/TP.0b013e31821694b3","article-title":"Current trends in living donor liver transplantation for primary sclerosing cholangitis","volume":"91","author":"Goldberg","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2023.07.008_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrgastro.2017.2","article-title":"Living donor liver transplantation: eliminating the wait for death in end-stage liver disease?","volume":"14","author":"Fisher","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.07.008_bib43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ajt.16864","article-title":"And the European liver and intestine transplant association (ELITA). Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: experience from the European Liver Transplant Registry","volume":"22","author":"Heinemann","year":"2022","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cld.2023.07.008_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/lt.23827","article-title":"Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy","volume":"20","author":"Sutton","year":"2014","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.cld.2023.07.008_bib45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/tri.12513","article-title":"Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis","volume":"28","author":"Pandanaboyana","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.cld.2023.07.008_bib46","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2023.07.008_bib47","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/tri.13925","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation \u2013 analysing the European Liver Transplant Registry and beyond","volume":"34","author":"Visseren","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.cld.2023.07.008_bib48","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.15148","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"49","author":"Steenstraten","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"28","key":"10.1016\/j.cld.2023.07.008_bib49","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.3748\/wjg.v24.i28.3171","article-title":"Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients","volume":"24","author":"Buchholz","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2023.07.008_bib50","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/lt.23741","article-title":"Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.cld.2023.07.008_bib51","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ibd\/izz325","article-title":"Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes","volume":"26","author":"Peverelle","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.cld.2023.07.008_bib52","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural History of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"24","author":"Mouchli","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cld.2023.07.008_bib53","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3748\/wjg.v20.i13.3525","article-title":"Clinical management of inflammatory bowel disease in the organ recipient","volume":"20","author":"Indriolo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2023.07.008_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:23Z","timestamp":1761069683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1089326123000880"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.07.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Primary Sclerosing Cholangitis Including Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}